Ultrathin strut biodegradable-polymer sirolimus-eluting stents: being wary or going with the flow?

In 2017, the cardiology community celebrated the 40th anniversary of the first coronary angioplasty by Grüntzig in Zurich, Switzerland (1). During this period of time, percutaneous coronary intervention (PCI) rapidly progressed from plain balloon angioplasty to bare-metal and drug-eluting stent (DES) platforms, the latter being a first-line therapy for patients presenting with anatomically suitable obstructive disease of coronary arteries (2).